Drug Delivery Devices Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2034

The drug delivery devices are specialized tools that are designed to introduce therapeutic substances into the body in a controlled manner. These devices are engineered to optimize the release and absorption of medications, ensuring that the correct dosage reaches the targeted side with precision and efficiency. Medications can be taken in a variety of ways—by swallowing, by inhalation, by absorption through the skin, or by injection. Drug delivery systems can also describe the way that drugs are ‘packaged’—like a micelle or a nanoparticle—that protects the drug from degradation and allows it to travel wherever it needs to go in the body. The development of drug delivery device utility advanced the field of medicine offering improve treatment outcomes and enhanced patient compliance.  

MARKET OVERVIEW

The market valuation of drug delivery devices market was valued at approximately USD 281.9 billion in 2023 and is projected to reach USD 463.1 billion in 2034 exhibiting a CAGR of 5.1% during the forecast period of 2024-2034. Drug delivery devices represent a critical intersection of engineering and pharmacology which aims to improve the efficacy and safety of therapeutic interventions. The market is aligned with healthcare sector, which makes it a sustainable and growing market. 

GROWTH DRIVERS

The technological advancements in microelectronics, biotechnology and material science have significantly enhanced the functionality and efficiency of drug delivery devices. These innovations allow for precise targeting-controlled release and improve patient compliance, which is a significant driver for the adoption and growth of the market. According to NIH, recently drug delivery systems (DDS) are formulated using advanced technology to accelerate systemic drug delivery to the specific target site, maximizing therapeutic efficacy and minimizing off-target accumulation in the body. As a result, they play an important role in disease management and treatment. Recent DDS offer greater advantages when compared to conventional drug delivery systems due to their enhanced performance, automation, precision, and efficacy. They are made of nanomaterials or miniaturized devices with multifunctional components that are biocompatible, biodegradable, and have high viscoelasticity with an extended circulating half-life.

The rise in incidence of chronic disease like diabetes, cancer and respiratory disorders as escalated the demand for effective drug delivery systems. According to the World Health Organization (WHO), chronic diseases (NCDs) like cancer, diabetes, and chronic respiratory diseases are responsible for over 80% of premature deaths worldwide. These diseases account for 74% of all deaths globally, and 86% of deaths before age 70. In 2021, diabetes was responsible for over 103,000 deaths in the United States. The global aging population and for the market as older adults typically require more frequent and complex medication regimes. The global aging population is an irreversible trend where the number and percentage of people aged 60 and older is increasing.

According to the World Health Organization (WHO), the number of people aged 60 and older is expected to increase from 1 billion in 2019 to 1.4 billion by 2030 and 2.1 billion by 2050. The United Nations (UN) projects that the percentage of people aged 65 and older will increase from 10% in 2022 to 16% in 2050. The favorable regulatory standards and approvals from the regulatory bodies like FDA and EMA increasingly approving the new delivery devices, facilitating the entry into the market and boosting innovation. The FDA Center for Devices and Radiological Health (CDRH) has an Innovation program that aims to accelerate patient access to innovative medical devices, including drug delivery devices. The CDRH's mission is to ensure that patients and providers have access to safe, effective, and high-quality medical devices, and to facilitate medical device innovation. 

MARKET SEGMENTATION:

·         By Route of Administration- oral, inhalation, transdermal, injectable, ocular, nasal, topical and others

·         By Application- cancer, diabetes, respiratory diseases, cardiovascular diseases, infectious diseases, central nervous system disorders, pain management and others

·         By Distribution Channel- Direct sales, online sales, distribution and retail

·         By End-User- hospitals, clinics, diagnostic center and home care settings

·         By Region- North America, Europe, Asia Pacific, Middle East and Africa, South America

Drug Delivery Devices Market Segment By Route of Administration Review:

The oral drug delivery involves administering medication through the mouth to be absorbed via the digestive tract. This is the most common and convenient method for drug administration, providing ease of use and patient compliance. It is suitable for a wide range of drugs, including solid and liquid form. The inhalation drug delivery involves inhaling medication directly into the lungs, providing rapid absorption and onset of actions. This is commonly used for respiratory conditions like asthma and COPD.

The transdermal drug delivery involves administering drugs through the skin patches, gels or creams. The drug is absorbed into the bloodstream via the skin. It bypasses the digestive system, avoiding first pass metabolism in the liver. It provides such control and sustained relief of medication over time. The injectable drug delivery involves administering medication through injections. It provides fast and direct delivery of medication into the bloodstream of tissues and suitable for a wide range of drugs including biologics and vaccines. The ocular drug delivery involves administering medication directly to the eye for the treatment of ocular diseases.

This includes eye drops, ointments and intraocular injections. It directly targets ocular tissues, providing effective treatment for eye conditions. The nasal drug delivery involves administering medication through the nasal passages. This route is used for both local and systemic drug delivery. The nasal mucosa provides a rich blood supply, allowing for quick absorption of medication. The topical drug delivery involves applying medication delivery through skin or mucous membranes. This root is the commonly used for local treatment or skin conditions and infections.

Drug Delivery Devices Market Segment By Application Review:

The drug delivery devices and cancer treatment are designed to deliver chemotherapeutic agents, targeted therapies, and immunotherapies directly to tumor sites, enhancing the efficiency and minimizing side effects. The devices such as implantable pumps and localized delivery system to ensure that high concentrations of the drug reach the tumor while sparing healthy tissues. The diabetes management heavily relies on drug delivery devices like insulin pens, pumps, and continuous glucose monitors to administer insulin and monitor blood glucose levels.

The insulin pumps provide precise dosing and can be programmed to deliver insulin based on the patient needs. The drug delivery systems for respiratory diseases like asthma and COPD include inhalers, nebulizers that delivers medication directly to the lungs. It provides quick relief from symptoms by delivering bronchodilators and corticosteroids directly to the airways. The drug deliveries devices in the cardiovascular disease include stents, drug eluting balloons and patches that deliver medication to the heart and blood vessels. The devices like drug eluting stents release medication at the site of arterial blockage and prevents the risk of restenosis.

Drug delivery devices for infectious diseases include syringe, infusion pumps and implantable devices that administer antibiotics, antivirals and vaccines. These devices ensure accurate and controlled delivery of medication essential in treating severe infections. The drug delivery devices for central nervous system disorders such as Parkinson's disease and epilepsy includes infusion pumps, transdermal patches and implantable devices. The devices like deep brain stimulators deliver medication directly to the specific brain regions, improving the treatment efficacy. The drug delivery devices for pain management like transdermal patches, infusion pumps, and implantable devices that administer analgesics and anesthetics.

Drug Delivery Devices Market Segment By Distribution Channel Review:

The direct sales involves manufacturers selling their drug delivery devices directly to the healthcare providers, hospitals and clinics without any middleman. This channel typically includes large volume transactions and large term contracts. The manufacturers offer tailored solutions and provide dedicated support and training for healthcare professions, ensuring proper usage and integration of devices. The online sales encompass ecommerce platforms and the manufacturer’s own websites where drug delivery devices are sold directly to the consumers, healthcare providers and others. The online platforms provide easy access to a wide range of products, allowing the customers to browse and purchase devices from anywhere at any time.

The e-commerce expands the geographical reach of the manufacturers in enabling them to serve underserved markets. The distribution involves third party distributors who purchase drug delivery devices from manufacturers and sell them to healthcare providers, pharmacies and retail outlets. The distributors often manage logistics, warehousing and inventory. They have established networks and relations with the healthcare industry, helping manufacturers reach a broader audience and penetrate raw materials. The retail channel includes pharmacies, medical supply stores and specialized retail outlets that sell drug delivery devices directly to the consumers.

Drug Delivery Devices Market Segment By End-User Review:

The hospitals are major end users of drug delivery devices due to the high volume of patients and the need for diverse treatment options. They require a wide range of devices for various therapeutic areas and patient needs. The clinics, including outpatient as well as specialized care centres, uses drug delivery devices for routine treatments and minor procedures. They cater to a broad spectrum of patients and medical conditions. The diagnostic centers primarily focuses on testing and early diagnosis of diseases. They use drug delivery devices to administer diagnostic agents and contrast media for imaging procedures. The home care settings involves patient managing their treatments at home often for chronic conditions. The drug delivery devices for are often user friendly and safe for self-administration.

Drug Delivery Devices Market Regional Analysis:

North America is a significant market driven by the factors like presence of robust and well-established healthcare sector coupled with high prevalence of chronic diseases. According to the World Health Organization (WHO), chronic diseases (NCDs) like cancer, diabetes, and chronic respiratory diseases are responsible for over 80% of premature deaths worldwide. In 2021, diabetes was responsible for over 103,000 deaths in the United States. Europe is valuable market driven by the factors like strong healthcare infrastructure and aging population. For instance, the population aged 60 and older projected to grow from 215 million in 2021 to 247 million by 2030 and over 300 million by 2050.

This demographic shift has been apparent for decades and is driven by a number of factors, including low fertility rates, increasing life expectancy, and migratory patterns, according to WHO. Asia Pacific is a rapidly growing market driven by the factors like rising healthcare expenditure and rise in disposable income coupled with growing prevalence of chronic diseases. According to NIH and APACMed, chronic diseases, are a growing concern in the Asia Pacific (APAC) region. They are a major cause of death and disease burden, some of the most common NCDs in the region includes cardiovascular diseases, diabetes, cancer, and chronic respiratory conditions. According to WHO, in the region, 62% of all deaths are due to NCDs accounting for 9 million persons. The Middle East and Africa is a promising market driven by the investments in infrastructure development including healthcare infrastructure. South America is a growing market driven by the healthcare infrastructure improvement. Rising prevalence of chronic diseases.

Key Challenges:

The drug delivery devices must adhere to stringent regulatory standards set by agencies like FDA, EMA and other global health authorities. These regulations ensure safety application quality but may pose significant barrier for the products in the entry of the markets. Navigating complex regulatory frameworks may be time consuming and costly, delaying the launch of new products. Additionally, maintaining compliance with every evolving regulation requires continuous investment in quality control and regulatory expertise. The development of innovative drug delivery devices involves substantial financial research and development expenditure, which includes clinical trials, material cost and engineering design. This financial burden may be a significant barrier, mainly for smaller companies. These high development cost may limit the availability of small players to innovate and compete leading to market domination by larger companies with greater financial resources.

Competitive Landscape:

In the highly competitive drug delivery devices market, companies are investing heavily in research and development to innovate and improve the product and services. They are also collaborating, forming strategi partnerships, or acquiring other companies to gain access to new market segments, enhance distribution networks, and increase market share.  The news and development include - In June 2023, Stevanato Group has launched Vertiva, a customizable platform for drug distribution, which is suitable for a wide range of therapies and large approach volumes. In December 2022, Biocorp received US FDA approval for its smart sensor Mallya. In May 2021, Gerreshmeimer collaborated with SensAir for on-body drug delivery platformwhich can deliver high viscosity drugs. In June 2022, Gufic Biosciences Ltd launched a new drug delivery system, Dual Chamber Bags, at affordable prices for the first time in India. In February 2022, Takeda received US FDA approval for TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS), which is used to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Global Key Players:

·         Pfizer

·         Johnson & Johnson Services

·         F. Hoffmann-La Roche

·         Novartis

·         Baxter

·         Bayer AG

·         Uniqure NV

·         Becton Dickson & Company

·         Sibiono Genetech Co.

·         Medtronic

·         Nemrara

·         Other Players

Attributes	Details
Base Year	2023
Trend Period	2024 – 2034
Forecast Period	2024 – 2034
Pages	215
By Route of Administration	oral, inhalation, transdermal, injectable, ocular, nasal, topical and others
By Application	cancer, diabetes, respiratory diseases, cardiovascular diseases, infectious diseases, central nervous system disorders, pain management and others
By Distribution Channel	Direct sales, online sales, distribution and retail
By End-User	hospitals, clinics, diagnostic center and home care settings
By region	North America, Europe, Asia Pacific, the Middle East and Africa, and South America
Company Profiles	Pfizer, Johnson & Johnson Services, F. Hoffmann-La Roche, Novartis, Baxter, Bayer AG, Uniqure NV, Becton Dickson & Company, Sibiono Genetech Co., Medtronic, Nemrara, Other Players
Edition	1st edition
Publication	July 2024